Evidence map›Paper›PMID 35474619›Full record

ArticleTransfusion medicine (Oxford, England)2022

Diagnostic accuracy of Abbott Architect Assay as a screening tool for human T-cell leukaemia virus type-1 and type-2 infection in a London teaching hospital with a large solid organ transplant centre.

Nathaniel Lee, Jamie Murphy, Rasheed Al-Khudairi, Ann Sturdy, Tabitha Mahungu, Tanzina Haque, Paul Griffiths, Jennifer Tosswill, Dianne Irish

Open access · hybridAbstract read
In one paragraph

Article in Transfusion medicine (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Human T-Lymphotropic Virus Screening of Blood Donations in England Between 2002 and 2021-Comparison of Screening Strategies.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Nathaniel LeeRoyal Free Hospital NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0002-4393-6891
Jamie MurphyRoyal Free Hospital NHS Foundation Trust, London, UK.
Rasheed Al-KhudairiRoyal Free Hospital NHS Foundation Trust, London, UK.
Ann SturdyRoyal Free Hospital NHS Foundation Trust, London, UK.
Tabitha MahunguRoyal Free Hospital NHS Foundation Trust, London, UK.
Tanzina HaqueRoyal Free Hospital NHS Foundation Trust, London, UK.
Paul GriffithsRoyal Free Hospital NHS Foundation Trust, London, UK.
Jennifer TosswillDepartment of Virology, UK Health Security Agency, London, UK.
Dianne IrishRoyal Free Hospital NHS Foundation Trust, London, UK.
Royal Free London NHS Foundation Trust · GBNational Security Agency · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimIn the United Kingdom, organ donors/recipients are screened for evidence of human T-cell leukaemia virus type-1 and type-2 (HTLV-1/2) infections. Since the United Kingdom is a low prevalence country for HTLV infections, a screening assay with high sensitivity and specificity is required. Samples with repeat reactivity on antibody testing are sent to a reference lab for confirmatory serological and molecular testing. In the case of donor screen, this leads to delays in the release of organs and can result in wastage. We aim to assess whether a signal/cut-off (S/CO) ratio higher than the manufacturer's recommendation of 1.0 in the Abbott Architect antibody assay is a reliable measure of HTLV-1/2 infection.

methodsWe conducted a 5 year retrospective analysis of 7245 patients from which 11 766 samples were tested on the Abbott Architect rHTLV I/II assay. Reactive samples (S/CO >1) were referred for confirmatory serological and molecular detection (Western Blot and proviral DNA) at UK Health Security Agency, (formerly PHE, Colindale), the national reference laboratory. Electronic, protected laboratory and hospital patient databases were employed to collate data.

resultsA total of 45 patients had initially reactive samples. 42.2% (n = 19/45) had an S/CO ratio > 20, with HTLV infection confirmed in n = 18/19 and indeterminate confirmatory results in n = 1/19. No samples with an S/CO ratio <4 (48.9%, n = 22/45) or 4-20 (8.9%, n = 4/45) had positive confirmatory results on subsequent confirmatory testing.

conclusionSamples with an S/CO >20 likely represent a true HTLV-1/2 infection. Reactive samples with an S/CO <4 were unlikely to confirm for HTLV infections. Interpretation of these ratios can assist clinicians in the assessment of low reactive samples and reiterates the need for faster access to confirmatory testing.

Indexed as

Deltaretrovirus InfectionsHTLV-II InfectionsHTLV-I InfectionsHuman T-lymphotropic virus 1Leukemia, T-CellOrgan TransplantationBlood DonorsHospitals, TeachingHumansHuman T-lymphotropic virus 2LondonRetrospective StudiesHTLV-1/2screeningtransplant

Identifiers

PMID35474619
PMCPMC9321154
OpenAlexW4224949081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.